ASCT2 has been implicated in rapidly growing cancer cells as a supply mechanism for glutamine, and inhibition of the transporter was shown to reduce cell proliferation and tumor size (Bröer et al., 1999; Son et al., 2013; Wahi and Holst, 2019; Kanai et al., 2013). This evidence concerns the gene SLC1A5 and neoplasm.